Mannkind Corp Dossier - Source-backed chat

Mannkind Corp

MNKDNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.07

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.95Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $1.3B

Enterprise Value $1.5B

Shares Outstanding 310.5M diluted

Next Earnings Date4 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

MannKind Corporation is undergoing a significant corporate transformation, transitioning from a single-product company to a diversified biopharmaceutical leader focused on cardiometabolic and orphan lung diseases. The investment thesis is anchored by the commercial expansion of Furoscix (following the scPharmaceuticals acquisition), the continued strong royalty stream from United Therapeutics for Tyvaso DPI, and the newly approved pediatric indication for Afrezza. With a catalyst-rich 2026, including the upcoming PDUFA date for the Furoscix ReadyFlow Autoinjector and clinical readouts for Nintedanib DPI, MannKind is well-positioned for sustained, long-term revenue growth and value creation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.75

Mean target$7.97

High · most bullish analyst$13.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects potential commercial execution risks, where Furoscix sales are hampered by persistent prior authorization hurdles and slower-than-expected adoption of the ReadyFlow Autoinjector. Afrezza pediatric uptake could be slow due to the challenge of educating pediatric endocrinologists, 95% of whom have never prescribed inhaled insulin. Clinical delays or safety concerns in the MNKD-201 pipeline would further depress valuation.

Base CaseCentral scenario

The base case assumes successful commercial execution of Furoscix, reaching the guided $110M-$120M range for FY 2026, and steady growth of Afrezza driven by the newly approved pediatric indication. Royalties from Tyvaso DPI remain robust, and the Furoscix ReadyFlow Autoinjector receives FDA approval on its July 26, 2026 PDUFA date, scaling the brand's growth trajectory in the second half of the year.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Diversified commercial portfolio with high-growth assets (Afrezza, Furoscix, and Tyvaso DPI royalties)
Recent FDA approval of Afrezza for pediatric use (ages 6+) opening a large, underserved market
Strong validation of the proprietary Technosphere drug-delivery platform through expanded partnerships with United Therapeutics

Key Investment Risks

High dependence on commercial execution and market adoption of newly launched products
Clinical trial and regulatory approval risks for pipeline candidates like Nintedanib DPI (MNKD-201)

Thesis Invalidation Triggers

FDA Complete Response Letter (CRL) or significant approval delay for the Furoscix ReadyFlow Autoinjector in July 2026
A material decline in Tyvaso DPI royalty revenues from United Therapeutics
Failure of the pediatric Afrezza launch to gain commercial traction in the first 12 months post-approval
Negative safety signals or failure to meet endpoints in the Phase 1b/2 trials for Nintedanib DPI

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.